DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

References

Saura C, Oliveira M, Feng YH. et al NALA Investigators.
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial.

J Clin Oncol 2020;
38 (27) 3138-3149

Download Bibliographical Data

Access:
Access: